GPM confirmed the presence of both IGH::BCL2 (Figure 2F) and PAX5::MYC (Figure 2G), along with 11q aberrations (Figure 2H) and other complex genomic abnormalities, supporting a diagnosis of DLBCL/high-grade B-cell lymphoma with MYC and BCL2 rearrangements. Here, BCL2 is linked to B-cell non-Hodgkin lymphoma.